BackBright Minds Biosciences Overview

Bright Minds Biosciences Total Liabilities

Track Bright Minds Biosciences's total liabilities ($2.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$2.55M
281.54% YoYΔ $1.88M vs prior year quarter

Peer trimmed avg / median

Loading

Bright Minds Biosciences Total Liabilities History

Loading

Bright Minds Biosciences vs. peers: Total Liabilities Comparison

Loading

Bright Minds Biosciences Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bright Minds Biosciences (DRUG) FAQ

Bright Minds Biosciences's total liabilities stands at $2.5M as of June 2026. That compares with $670K in the prior-year period — up 281.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Bright Minds Biosciences reported $2.5M in total liabilities versus $670K a year earlier — a 281.5% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $670K in the prior-year period — up 281.5% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Bright Minds Biosciences's total liabilities evolved across reporting periods, while the comparison chart places DRUG next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Bright Minds Biosciences's reading of $2.5M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.